McGuire, William P <br/><br/>
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.  [electronic resource] 

 -  BMC cancer  Dec 2018 
 - 1292 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/s12885-018-5198-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Carcinoma, Ovarian Epithelial--drug therapy<br/>Cisplatin--pharmacology<br/>Constipation--chemically induced<br/>Doxorubicin--analogs & derivatives<br/>Drug Resistance, Neoplasm<br/>Fatigue--chemically induced<br/>Female<br/>Humans<br/>Middle Aged<br/>Mucositis--chemically induced<br/>Nausea--chemically induced<br/>Neoplasm Recurrence, Local--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Polyethylene Glycols--pharmacology<br/>Progression-Free Survival<br/>Receptor, Platelet-Derived Growth Factor alpha--antagonists & inhibitors<br/>Time Factors